Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

Eli Lilly crushed Q1 and raised guidance again.

EPS: $8.55 vs $6.66 expected

Revenue: $19.8B vs $17.62B expected (+56% YoY)

Stock up 5% premarket

Main driver was GLP-1 demand:
Mounjaro: $8.66B revenue (+125%), beat estimates

Zepbound: $4.16B US revenue (+80%), also beat
Lilly now expects 2026 revenue of $82B–$85B (was $80B–$83B) and adjusted EPS of $35.50–$37 (was $33.50–$35).
They currently hold about 60% of the US obesity/diabetes GLP-1 market, ahead of Novo at 39%.

Even with lower prices, demand keeps ripping. New obesity pill Foundayo just launched, so next earnings call will probably focus on whether it can become another monster product.